Navigation Links
ACell and Medline Announce Exclusive Marketing and Distribution Agreement for MatriStem(TM) Proprietary Bioscaffold for Wound Care
Date:3/23/2009

COLUMBIA, Md. and MUNDELEIN, Ill., March 23 /PRNewswire/ -- ACell, Inc. and Medline Industries, Inc. jointly announced today that Medline has signed an exclusive marketing and distribution agreement for ACell's MatriStem(TM) Wound Care Matrix. Under the agreement, ACell will manufacture and Medline will market and distribute the products.

ACell's MatriStem regenerative medicine technology is a naturally occurring bioscaffold derived from porcine tissue. When MatriStem is placed onto a wound, it is resorbed and replaced with new native tissue where scar tissue would normally be expected. MatriStem devices, currently available in sheet and powder form, can be used in a broad range of medical applications such as wound care, general surgery, gastrointestinal surgery, urology and plastic and reconstructive surgery.

MatriStem Wound Care Matrix facilitates the healing process and is used on partial and full-thickness wounds such as diabetic, venous, arterial and pressure ulcers, and first and second-degree burns. The infected foot ulcer is the most common reason for hospitalization among patients with diabetes, resulting in over 200,000 days of inpatient care. Diabetes related amputations cost the health care system approximately $3 billion a year. Wound care devices, home health care and hospital costs associated with wound care, cost the U.S. healthcare system over $7 billion in 2007.

"As a well-established advanced wound care company, Medline will be an excellent partner for marketing and distributing our MatriStem Wound Care Matrix," stated Jim DeFrancesco, President and CEO of ACell, Inc. "We look forward to utilizing our unique regenerative medicine technologies in future collaborative efforts with Medline for creating additional advanced wound care products."

Jonathan Primer, President of Medline's Wound Care Division, commented, "We are pleased to announce our exclusive agreement with ACell to market and distribute its proprietary MatriStem Wound Care Matrix. The MatriStem preclinical studies are innovative in the field of bioscaffolds and we look forward to partnering with ACell to continue the advancement of wound care research."

About ACell

ACell, headquartered in Columbia, MD, offers a range of medical devices based on its patented and proprietary extracellular matrix technologies. MatriStem devices have received FDA clearances for applications in wound care, soft tissue repair, and general surgery. The devices are manufactured in ACell's cGMP facility based in Lafayette, IN. For more information on ACell, visit our website, www.acell.com.

About Medline

Medline, headquartered in Mundelein, IL, manufactures and distributes more than 100,000 products to hospitals, extended care facilities, surgery centers, home care dealers and agencies and other markets. Total revenue for Medline in 2007 exceeded $2.86 billion. Meeting national and international quality standards, Medline is FDA QSR compliant and ISO 13485 certified. Medline serves on major industry quality committees to develop guidelines and standards for medical product use, including the FDA Midwest Steering Committee, AAMI Sterilization and Packaging Committee, and various ASTM committees. For more information on Medline, visit our website, www.medline.com.


'/>"/>
SOURCE ACell, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Seahorse XF96 Extracellular Flux Analyzer Wins Best New Product Award for DRUG DISCOVERY at 2009 Molecular Medicine Conference
2. Alfacell Announces Receipt of NASDAQ Panel Decision
3. Alfacell Announces Management Update
4. Alfacell Reports Financial Results for First Quarter of Fiscal 2009
5. Duracell and Actress Maggie Gyllenhaal Announce Winners of Power A Smile Casting Call After Nationwide Search for Five Child Holiday Ambassadors
6. SpectraCell Laboratories Expands Operations in New Facility
7. SpectraCell Laboratories Offers Additional Test for Heart Attack and Stroke Risk
8. Arthritis Foundation Grants Ease-Of-Use Commendation to Duracell EasyTab Hearing Aid Battery
9. Dr. Wei Sun, PhD, MD Joins SpectraCell Laboratories
10. Anti-Aging/Genetic Health Leader Suracell, Inc. Expands Internationally
11. Protein-dependent switch regulates intracellular trafficking in epithelial cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... MD Now Urgent Care ... MD Now’s 28th facility overall and marks the urgent care center's eighth location in ... North of The Falls shopping mall. The new clinic offers a wide array of ...
(Date:6/23/2017)... ... ... American Farmer, will feature Chr. Hansen, Inc (CHR Hansen) in an upcoming episode ... Farmer airs Tuesdays at 8:30aET on RFD-TV. Check your local listings for more info. ... 1874 after a groundbreaking discovery of how to industrialize enzymes. Rooted in science and ...
(Date:6/23/2017)... Chicago, IL (PRWEB) , ... June 23, 2017 ... ... insurance management assistance and financial planning services to communities in the greater Chicago ... Children’s Association to offer assistance to underprivileged youth in Chicago. , Founded in ...
(Date:6/23/2017)... ... June 23, 2017 , ... Moore Insurance, ... area with access to asset protection and financial planning services, is teaming up ... improving the lives of children with cancer and other chronic diseases. , The ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... is pleased to welcome Whipple & Company as its newest Partner Firm. Headquartered ... of balancing their clients’ risk while tailoring optimized benefit packages that strengthen the ...
Breaking Medicine News(10 mins):
(Date:6/2/2017)... , June 2, 2017  NxStage Medical, Inc. (Nasdaq:  NXTM), a ... today announced new findings demonstrating positive biochemical outcomes related ... System One™. The data will be presented at the ... Madrid, Spain . The ... Home Dialysis Network in Europe ...
(Date:5/29/2017)... Israel, May 29, 2017  Cellect Biotechnology Ltd. (NASDAQ: ... technology which enables the functional selection of stem cells, ... for the first quarter ended March 31 st , ... our accomplishments in the first quarter of 2017," said ... quarter, we announced the treatment of the first blood ...
(Date:5/22/2017)... VALLEY COTTAGE, N.Y. , May 22, 2017 ... natural antiviral treatment Gene-Eden-VIR/Novirin, announces the launch of ... in plain English, the results of a clinical ... after one year treatment with Gene-Eden-VIR/Novirin in individuals ... is important to note that there are no ...
Breaking Medicine Technology: